Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04912076Phase 1Completed

S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen

Role: collaborator

NCT02643641Phase 2Completed

Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response

Role: lead

NCT01350635Phase 1Completed

Skin Test Study of BM32

Role: lead

NCT01538979Phase 2Completed

Phase II Study of Grass Pollen Allergy Vaccine BM32

Role: lead

NCT01445002Phase 2Completed

Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

Role: lead

All 5 trials loaded